Q2 2025 Laboratory Corp of America Holdings Earnings Call
Operator: Call. At this time, all participants are in a listen-only mode.
Operator: After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again.
Operator: Please be advised that today's conference is being recorded.
Good day, and thank you for standing by, welcome to the Q2 2025 Lab Corp Holdings earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session to ask a question during the session. You will need to press star 1, 1 on your telephone. You will then hear an automated message. Advising your hand is raised to withdraw your question. Please press star 1 1 again.
Kristen O'Donnell: I would now like to hand the conference over to your speaker today, Kristen O'Donnell, Vice President of Investor Relations. Please go ahead. Thank you, Operator.
Speaker Change: Please be advised, that today's conference is being recorded. I would now like to hand the conference over to your speaker today. Christina Donnell, vice president of investor relations. Please go ahead.
Kristen O'Donnell: Good morning and welcome to LabCorp's second quarter 2025 conference call.
Kristen O'Donnell: As detailed in today's press release, there will be a replay of this conference call available.
Kristen O'Donnell: With me today are Adam Schechter, Chairman and Chief Executive Officer, and Julia Wang, Executive Vice President and Chief Financial Officer. This morning in the Investor Relations section of our website at www.labcorp.com, we posted both our press release and an Investor Relations presentation with additional information on our business and operations, which include a reconciliation of the non-GAAP financial measures to the most comparable GAAP financial measures, both of which are discussed during today's call. Please see the Use of Adjusted Measures section in our press release and Investor Relations presentation for more information regarding our use of non-GAAP financial measures.
Christina Donnell: Thank you, operator. Good morning and welcome to labcore second quarter 2025 conference call as detailed in today's press release, there will be a replay of this conference call available with me today. Our Adam Sher chairman and chief executive officer and Julia Wong, Executive Vice President and Chief Financial Officer. This morning in the investor relations section of our website at www.labcorp.com. We posted both our press release and an investor relationship.
Kristen O'Donnell: Additionally, we are making forward-looking statements. These forward-looking statements include, but are not limited to, statements with respect to the estimated 2025 guidance and the related assumptions, the projected impact of various factors on the company's businesses, operating and financial results, cash flows, and or financial condition, including global economic and market conditions, future business strategies, expected savings, benefits and synergies from the Launchpad Initiative and from acquisitions and other strategic transactions and partnerships, the completed holding company reorganization and opportunities for future growth. Each of the forward-looking statements is subject to change based upon various factors, many of which are beyond our control.
Presentation with additional information on our business and operations which include a Reconciliation of the non-gaap financial measures to the most comparable, gaap Financial measures, both of which are discussed. During today's call, please see the use of adjusted measures section in our press release and investors relations presentation. For more information regarding our use of non-gaap financial measures
Kristen O'Donnell: More information is included in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q and in the company's other filings with the FAA. We have no obligation to provide any updates to these forward-looking statements, even if our expectations...
Adam Schechter: Now we'll turn the call over to Adam. Thank you, Kristen. And good morning, everyone. We appreciate you joining us today to discuss our second quarter financial results and progress on our strategy. During the quarter, we delivered double-digit top-line growth and solid margin expansion. Our financial results reflect continued strength of our diagnostic laboratories business. and momentum in our biopharma laboratory services. Enterprise revenue reached $3.5 billion, representing 10% growth versus last year. Diagnostics revenue grew 9%, reaching $2.7 billion, driven equally by organic growth and acquisition. Margin improved slightly, including the impact from a VTAC. and Envite continues to perform very well and remains on track.
Christina Donnell: Additionally, we are making forward-looking statements these forward-looking statements include but are not limited to statements, with respect to the estimated 2025 guidance. And the related assumptions, the projected impact of various factors on the companies businesses operating and financial results, cash, flows, and or financial conditions including global economic and market conditions future business. Strategies expected savings benefits. And synergies from the Launchpad initiative, and from Acquisitions and other strategic transactions, and Partnerships. The completed Holden company reorganization, and opportunities for future growth. Each of the forward-looking statements is subject to change based upon various factors, many of which are beyond our control. More information is included in our most recent annual report on form 10K and subsequent quarterly reports on form 10q. And then the company's other filings with the SEC. We have no obligation to provide any updates to these 4 looking statements, even if our expectations change. Now, I'll
Adam Sher: Turn the call over to Adam Sher.
Adam Sher: Thank you Kristen and good morning everyone. We appreciate you joining us today to discuss our second quarter Financial results and progress on our strategy.
Adam Sher: During the quarter, we delivered double-digit Topline growth and solid margin expansion.
Adam Sher: Our financial results, reflect continued, strength of our diagnostic, laboratories business and momentum. In our biofarma laboratory services business,
Adam Sher: And Enterprise Revenue reached 3.5 billion, dollars representing 10% growth versus last year.
Adam Sher: Diagnostics Revenue, grew 9%, reaching 2.7 billion dollars, driven equally, buy organic growth and acquisitions.
Adam Schechter: BLS delivered strong revenue performance and grew 11% or 8% constant currency to $785 million. while margins improve 50 basis. Central Laboratories grew 8% or 4% constant currency, and early development grew 20% or 18% constant currency. Importantly, the quarterly book-to-bill was strong at 1.18, with a trailing 12-month of 1.11. Enterprise Margin Improved 20 Basis Points. An adjusted earnings per share of $4.35 grew 10% year over year. Based upon our performance year-to-date and our expectations for the second half of the year.
Adam Sher: And it'll be take continues to perform very well and remains on track.
Adam Sher: Bose delivered, strong Revenue performance, and grew 11%, or 8% constant currency to 785 million while margins improved 50 basis points,
Adam Sher: Central Laboratories grew 8% or 4%. Constant currency and early development, grew, 20%, or 18% constant currency.
Adam Sher: Importantly, the quarterly book. The bill was strong at 1.18 with a trailing 12-month of 1.11.
Adam Sher: Enterprise margin improved, 20 basis points and adjusted earnings per share of $4.35 grew, 10% year-over-year.
Adam Sher: Performance year to date.
Adam Schechter: We are raising our enterprise guidance.
Adam Sher: And our expectations for the second half of the year.
Adam Schechter: Julie will provide more details on the results and full year 2025 outlook in just a moment.
Adam Sher: We are raising our Enterprise guidance.
Adam Schechter: But first, I'll highlight how our strategy is continuing to enable our growth and our leadership in the industry. First, in our Diagnostics Laboratory segment. One of our objectives is to be the partner of choice for health systems and regional and local laboratories. by focusing on these customers. We've expanded our presence in hospitals, we've strengthened customer relationships, and we've brought in patient access in key geographies, which helps improve patient outcomes and also accelerate growth. through technology solutions such as LabCorp Diagnostic Assistance. We've been able to provide data and analytics and important insights to our customers. Many of these customers are thought leaders in specialty areas and our collaboration with them mutually benefits our collective scientific expertise.
Adam Sher: Julie will provide more details on our results and full year 2025 Outlook in just a moment.
Speaker Change: But first, I'll highlight how our strategy is continuing to enable our growth and our leadership in the industry.
Speaker Change: first, in our Diagnostics laboratory segment,
Speaker Change: 1 of our objectives is to be the partner of choice for health systems and Regional local Laboratories.
Speaker Change: By focusing on these customers, we've expanded our presence in hospitals. We've strengthened customer relationships and we've brought in patient access in key geographies which helps improve patient outcomes and also accelerate growth
Speaker Change: Through Technology Solutions. Such as labwork diagnostic assistance.
Speaker Change: We've been able to provide data and analytics and important insights to our customers.
Adam Schechter: In the quarter, we announced acquisitions and partnerships with several health systems and regional local laboratories, including. acquiring key clinical and anatomic pathology assets from Insight Diagnostics in the Pacific Northwest. extending our long-term agreement with UHealth, the University of Miami health system, to serve as their preferred laboratory partner. progressing our acquisition of select oncology and clinical testing assets for bio-referenced health. The transaction is on track to close in the second half of 2025. And subsequent to quarter end, we announced an agreement to acquire select assets of the outreach business from community health systems across 13 states.
Speaker Change: many of these customers are thought leaders in specialty areas and our collaboration with them mutually benefits, our Collective, scientific expertise,
Speaker Change: In the quarter. We announced Acquisitions and Partnerships with several Health Systems and Regional local Laboratories. Including
Speaker Change: Acquiring key clinical and anatomic pathology assets from incyte, Diagnostics in the Pacific Northwest.
Speaker Change: Extending our long-term agreement with you help.
Speaker Change: The University of Miami Health System to serve as their preferred laboratory partner.
Speaker Change: Progressing, our acquisition of Select oncology and clinical testing assets from bioreference health.
Speaker Change: The transaction is on track to close in the second half of 2025.
Adam Schechter: CHS is one of the largest health care companies in the United States.
Speaker Change: And subsequent to quarter end. We announced an agreement to acquire, select assets of the Outreach business from Community Health Systems across 13 states.
Adam Schechter: Looking ahead, we have a strong deal pipeline, and we look forward to sharing our progress in the coming quarter.
Speaker Change: CHS is 1 of the largest healthcare companies in the United States.
Adam Schechter: Second, we continue to launch new and innovative tasks in our specialty-focused areas, including oncology, women's health, neurology, and autoimmune diseases. This focus has helped to accelerate our growth in those categories as well as across our core testing portfolio as physicians utilize our broad test menu to meet the comprehensive needs of these patients. We have leading expertise, both scientifically and in the marketplace, in these areas, which also complements our BLS business. We partner with many pharmaceutical and biotechnology companies. as they develop novel therapeutics as well as products which require companion diagnosis. In the second quarter, we made important progress.
Speaker Change: Looking at, we have a strong deal Pipeline and we look forward to sharing our progress in the coming quarters.
Speaker Change: Second we continue to launch new and Innovative tests in our specialty focused areas, including oncology Women's Health neurology and autoimmune diseases.
Speaker Change: This Focus has helped to accelerate our growth in those categories as well as across our core testing portfolio as Physicians. Utilize our broad test menu to meet the comprehensive needs of these patients.
Speaker Change: We have leading expertise both scientifically and in the marketplace in these areas which also complements our BLS business. We partner with many pharmaceutical and biotechnology companies as they develop novel Therapeutics as well as products, which require companion Diagnostics
Adam Schechter: launching innovative tests in specialty areas, and introducing new capabilities to our customers. We expanded our oncology portfolio with new solutions for cancer detection, diagnosis, and monitoring. Key launches include expansion of our MRD portfolio through Blackboard Plasma Detect, a liquid biopsy test that assesses colon cancer recurrence risk. and PDX Allele Plasma Focus DX, the first and only FDA-authorized pan-solid tumor liquid biopsy test for targeted treatment guidance. We continue to advance our leading position in Alzheimer's disease and plan to offer Fuji Revio's FDA-cleared biomarker test that aids in diagnosing the disease in the coming week.
Speaker Change: in the second quarter, we made important progress.
Speaker Change: Launching Innovative tests in specialty, areas, and introducing new capabilities to our customers.
Speaker Change: We expanded our oncology portfolio with new solutions for cancer detection. Diagnosis and monitoring
Speaker Change: He launches include expansion of our mrd portfolio through Blackboard, plasma detect, a liquid biopsy test that assesses colon cancer recurrence risk.
Speaker Change: And PDX Elio, plasma Focus DX, the first and only FDA authorized pan. Solid tumor liquid biopsy test for targeted treatment guidance.
Adam Schechter: We also expanded our consumer office. We launched several consumer-initiated tests through LabCorp OnDemand. including tests that measure an individual's cortisol and leptin levels. We also introduced a new and improved Ovia app, providing women with a single platform to support their health journey. we introduce LabCorp Whole Health Solutions for Functional Medicine, Integrative Medicine, and Primary Care Practices. The solution offers specialized test panels and a test menu of more than 1,000 scientifically backed biomarkers for cardiometabolic health, hormones, micronutrients, longevity, and wellness. Finally, our central laboratory business added digital pathology capabilities, including advanced image scanning to preserve critical sample data, and AI-powered solutions to provide analysis on large datasets instantly.
Speaker Change: We continue to advance our leading position in Alzheimer's disease and plan to offer a Fuji review's FDA. Cleared biomarker test that aids in diagnosing. The disease in the coming weeks
Speaker Change: Also expanded our consumer offerings. We lost several consumer initiated tests through Labor on demand.
Speaker Change: Including tests that measure an individual's cortisol and leptin levels.
Speaker Change: We also introduced a new and improved ovia app providing women with a single platform to support their health Journey.
Speaker Change: We introduced lab for Whole Health Solutions for functional medicine, integrative medicine, and Primary Care practices.
Speaker Change: The solution offers specialized test panels and a test menu of more than 1,000 scientifically backed biomarkers for cardio. Metabolic Health hormones, micronutrients longevity and Wellness.
Adam Schechter: These enhancements complement our existing global anatomic pathology capabilities. Our full-service tissue-based test. and our companion diagnostic development across cancer, mass, and other diseases.
Speaker Change: finally, our Central laboratory business at a digital pathology capabilities including Advanced image scanning to preserve critical sample data and AI powered solutions to provide analysis on large data, sets instantly
Speaker Change: These enhancement, complements our existing Global anatomic. Pathology capabilities.
Adam Schechter: And third, we are focused on enhancing customer and employee experiences and leveraging technology to drive ongoing operational and process efficiency. We're using digital technologies and AI to drive improvements in areas such as Net Promoter Score, our Launchpad initiative. and more. We expect to see continued benefits as we incorporate technology across our business.
Speaker Change: Our full service tissue based testing and our companion diagnostic Development Across cancer mass and other diseases.
Speaker Change: And third we are focused on enhancing customer and employee experiences and leveraging Technology to drive ongoing operational and process efficiencies.
Speaker Change: We're using digital Technologies and AI to drive improvements in areas such as net promoter score.
Speaker Change: Our Launchpad initiatives and margins.
Adam Schechter: To summarize, we delivered very strong results in the quarter and continue to make significant progress on our strategy. We remain committed to delivering sustained value to our customers, our employees, and our shareholders.
Speaker Change: We expect to see continued benefits as we incorporate technology across our business.
Speaker Change: To summarize.
Speaker Change: We delivered, very strong results in the quarter and continue to make significant progress on our strategy.
Julia Wang: With that, I'll turn the call over to Julia to discuss the financial results and 2025 outlook and further retail. Thank you, Adam. As Adam just shared in the opening remarks, we delivered strong underlying performance from both segments in the quarter as we have continued to win in the marketplace and execute against our strategy.
Speaker Change: We remain committed to delivering sustained value to our customers, our employees, and our shareholders.
Speaker Change: With that, I'll turn the call over to Julia to discuss our financial results and 2025 Outlook in further retail.
Julia Wong: Thank you Adam. As Adam just to share in the opening remarks.
Julia Wang: The Strongholder combined with favorable foreign enables us to raise our four-year vision. Now, let me start with a review of our Q2 financials. Revenue for the quarter was $3.5 billion, an increase of 9.5% compared to last year, driven by organic growth of 5.4%, the impact from acquisitions of 3.5%, and foreign currency translation of 0.6%. Operating income for the quarter was $395 million, or 11.2% revenue, which is 15.1% on an adjusted basis. During the quarter, we had $69 million of restructuring charges and special items. primarily related to acquisitions and launchpad initiatives. Excluding these items and amortization of $68 million, adjusted opening income in the quarter was $532 million.
Speaker Change: We delivered strong, underlying performance from both segments in the quarter as we have continued to win in the marketplace and execute against our strategy.
Speaker Change: The strong quarter combined with favorable foreign exchange rates enables us to raise our 4-year guidance.
Speaker Change: Now, let me start with the review of our Q2 financials.
Speaker Change: Revenue for the quarter was 3.5 million and the increase of 9.5% compared to last year.
Speaker Change: Driven by organic growth of 5.4%.
Speaker Change: The impact from Acquisitions of 3.5% and foreign currency translation of 0.6%.
Speaker Change: Operating income for the quarter was 395 million.
Speaker Change: For 11.2% of Revenue which is 15.1% on an adjusted basis.
Speaker Change: During the quarter, we had a 69 million of restructuring charges and special items.
Speaker Change: Primarily related to Acquisitions and launch pad initiatives.
Julia Wang: for 15.1% of running. compared to $480 million or 14.9% revenue last year. The increase in adjusted opening income was due to organic demand as we leveraged well on our revenue growth. Our launchpad initiative continues to be on track in the quarter, which offsets typical increases in personnel costs. Despite a 30 basis point headwind from Invitae, adjusted operating margin increased 20 basis The adjusted tax rate for the quarter was 23.1% compared to 23% last year. We continue to expect our adjusted tax rate for full year 2025 to be approximately 23%. Net earnings for the quarter were $238 million, or $2.84 per devoted share.
Speaker Change: Excluding this items and amortization of 68 million adjusted opening income in the quarter was 532 million.
Speaker Change: For 15.1% of Revenue.
Speaker Change: Compared to 418 million or 14.9% of Revenue last year.
Speaker Change: the increasing adjusted opening income was due to organic demand as we leveraged, well, our Revenue growth,
Speaker Change: Our launch pad initiative continues to be on tracking the quarter which offset typical increases in Personnel costs.
Speaker Change: despite a 30 basis point headwind from inviting adjusted opportunity, margin increased, 20 basis points,
Speaker Change: The adjusted tax rate for the quarter was 23.1%.
Speaker Change: Compared to 23% last year.
Speaker Change: We continue to expect our Justice tax rate for 4 year, 2025 to be approximately 23%.
Julia Wang: Adjusted EPS was $4.35 in the quarter, up 10.4% from last year as we leveraged well our revenue. Boston cash flow was $621 million in the quarter, compared to $561 million a year ago. Capital expenditures totaled $78 million in the quarter. For the full year, we continue to expect capital expenditures to be approximately 3.8% revenue. Free cash flow for the quarter was $543 million compared to $433 million last year. This $110 million increase in free cash flow was driven by higher earnings and the timing of capital expenditure. During the quarter, the company invested $25 million in acquisitions and partners.
Speaker Change: Net earnings for the quarter were 238 million or 2.84 cents per denoted. Share.
Speaker Change: Adjusted. The EPS was 4.35 cents in the quarter.
Speaker Change: Up to 10.4% from last year as we leveraged, well, our Revenue growth.
121 million in the quarter, compared to 561 million a year ago.
Speaker Change: Capital expenditures totaled 178 million in the quarter.
Speaker Change: For the 4 year, we continue to expect the capital expenditures to be approximately 3.8% for Revenue.
Speaker Change: Free cash flow for the quarter was 543 million compared to 433 Million last year.
Speaker Change: This 110 million increase in free. Cash flow was driven by higher earnings and the timing of capital expenditures.
Julia Wang: paid out $60 million in dividends and repurchased $200 million of stocks. At quarter end, we had $647 million in cash, while total debt was $5.6 billion. Our debt leverage as of quarter end was 2.5 times growth debt to trillion 12-month adjusted EBITDA at the low end of our targeted leverage range of 2.5 times to 3 times.
Speaker Change: During the quarter, the company invested, 25 million in Acquisitions and Partnerships.
Speaker Change: Paid out. 16 million dollars in dividends.
Speaker Change: And repurchased, 200 million dollars of stock.
Speaker Change: At quarter end, we had 647 million dollars in cash. While total debt was 5.6 billion dollars,
Our debt knowledge, as of quarter end was 2.5 times growth debt to training, 12 months, adjusted debt.
Julia Wang: Now I will review our segment performance, beginning with Diagnostics Laboratory. Revenue for the quarter was $2.7 billion, an increase of 8.9% compared to last year, with organic growth of 4.5% and acquisitions of 4.5%. partially offset by foreign currency translation of 0.1% Total volume increased 4.9% compared to last year, with organic volume contributing 3.4%, as we continue to execute our strategy and drive strong demand. Acquisitions contributed 1.5%. Price missed increase 4% versus last year due to organic growth of 1.1% and acquisitions of 3%. partially offset by foreign currency translation of 0.1%. Organic price mess was up due to mess, as we benefited from an increase in cost per accession and less management agreements.
Speaker Change: At the low end of our targeted. Leverage range of 2.5 times to 3 times.
Speaker Change: now, I do review, our segment performance beginning with diagnostic laboratories,
Speaker Change: Revenue for the quarter was 2.7 billion dollars.
Speaker Change: An increase of 8.9% compared to last year with Organic growth of 4.5% and Acquisitions of 4.5%.
Speaker Change: Positive offset by 4, currency translation of 0.1%.
Speaker Change: Total volume increased 4.9% compared to last year with Organic Wing contributing 3.4% as we continued to execute our strategy and drive strong demand.
Acquisitions contributed 1.5%.
Price, mixed increased 4% versus last year due to organic growth of 121% and Acquisitions of 3%.
Speaker Change: Partially offset by foreign currency translation of 0.1%.
Julia Wang: Diagnostics suggested opening income for the Porter was $483 million, or 17.6% of revenue, compared to $442 million, or 17.5% of revenue last year. Adjusted Operating Margin was up 10 basis points.
Speaker Change: Organic price match was up due to length. As we benefited from an increase in tax perception and less management agreements.
Speaker Change: Diagnostics adjusted opening, come for the porter, with 483 million.
Speaker Change: Or 17.6% of Revenue.
Speaker Change: Compared to 442 million or 17.5% of Revenue last year.
Julia Wang: We continue to be pleased with the progress we are making in Invitae, which will annualize next quarter. in which he remains on track to achieve 10% revenue growth and to be slightly equated for full year 2025. Excluding the impact of invading, margins would have been up approximately 50%.
Speaker Change: Adjusted operating margin was up 10 basis points.
Speaker Change: We continue to be pleased with the progress. We are making in in Latin, which will annualize next quarter.
Speaker Change: Inmate, he remains on track to achieve 10% Revenue growth and to be Thrive to the greatest for 4 year 2025.
Julia Wang: Now I will review the segmented performance of BioPharma Laboratory Services or BLS. Revenue for the quarter was $785 million, an increase of 11% compared to last year due to an increase in organic revenue of 7.8% and foreign currency translation of 3.2%. In constant currency, Central Labs revenue was up approximately 4%, while early development was up approximately 18%. The growth in early development was primarily driven by a relatively easy compared to prior year, as well as timing of study start.
Speaker Change: Excluding the impact of in meeting margins, would have been up approximately 50 basis points.
Speaker Change: Now, I will review the segment performance of bio for laboratory services of BLS.
Speaker Change: Revenue for the quarter was 785 million.
Speaker Change: And the increase of 11% compared to last year, due to an increase in organic revenue of 7.8%.
And the foreign currency translation of 3.2%.
Speaker Change: In constant currency Central Labs Revenue was up approximately 4% while early development was up approximately 18%.
Julia Wang: We still expect both businesses to grow in the mid-single digits on a constant currency basis for the full year, with early developments facing more challenging year-over-year comparisons, particularly in the fourth quadrant. BLS adjusted open income for the quarter with $123 million, or 15.7% of revenue. compared to $107 million or 15.2% of revenue last year. Adjusted Opening Income and Margin Increase Primarily Driven by Organic Demand and Operating Efficiency.
Speaker Change: The growth in early development was primarily driven by a relatively easy compared to Prior year as well as timing of study starts.
We still expect both businesses to grow in the mid single digits on the constant currency basis for the 4 year.
Speaker Change: with early development facing more challenging year-over-year comparisons particularly in the fourth quarter,
Speaker Change: BLS adjusted, the opening, come for the quarter was 123 million or 15.7% of Revenue.
Speaker Change: Compared to 107 million or 15.2% of Revenue last year.
Julia Wang: We ended the quarter with a backlog of $8.7 billion, and we expect approximately $2.7 billion of this backlog to convert into revenue over the next 12 months. Our sentiment-quality booked bill was drawn at 1.18. Bring the trading 12-month book to bail to 1.11. The strength was driven by several large Stardate Awards in Central Labs.
Speaker Change: adjusted the opening income and margin increased primarily driven by organic demand and operating efficiencies
Speaker Change: Month.
I was sending quality book to bill was strong at 1.18.
Speaker Change: Bring the training 12 months, booked to bail to 1.11.
Julia Wang: Now I will discuss our updated 2025 four-year guidance. which has seen foreign exchange rates effective as of June 30th of 2025 for the remainder of the year. The enterprise guidance also includes the impact from currently anticipated capital allocation, utilizing free cash flow for acquisitions, share repurchases, and dividends.
Speaker Change: The strength was driven by several large study Awards in central labs.
Speaker Change: Now, I will discuss our updated 2025 full year guidance.
Speaker Change: Which assumes foreign exchange rate effective as of June 30th of 2025 for the remainder of the year?
Julia Wang: Our guidance has taken into account various scenarios as the macro and regulatory landscape continues to evolve. We are raising guidance for enterprise revenue, adjusted EPS, and free cash flow. primarily driven by currency, as well as the underlying strength of our business. We raised the 2025 Enterprise Revenue Guidance by 70 basis points at the midpoint. and narrowed the growth range to 7.5% to 8.6% when compared to 2024. Diagnostics continues to execute well in the market. We raised diagnostics revenue guidance by 40 basis points at the midpoint. and narrowed the growth range to 7% to 8%. In BLS, we increased the midpoint by 280 basis points due to the favorable impact of foreign currency.
Speaker Change: The end point guidance also includes the impact from current anticipated. Capital, allocation utilizing free cash flow for Acquisitions. Share repurchases and dividends
Speaker Change: Our guidance has taken into account various scenarios as the macro and Regulatory landscape continues to evolve.
Speaker Change: We are raising guidance for Enterprise Revenue, adjusting the ups and free cash flow.
Speaker Change: Primarily driven by currency as well as the underlying strength of our businesses.
Speaker Change: We reached the 2025 Enterprise Revenue guidance by 70 basis points at the midpoint.
Speaker Change: And levels the growth range to 7.5% to 8.6% when compared to 2024.
Speaker Change: Diagnostics continues to execute well in the marketplace.
Speaker Change: we raised Diagnostics Revenue, guidance by 40 basis points at the midpoint,
Speaker Change: At narrowed, the growth range to 7% to 8%.
Julia Wang: and narrowed the growth range to 6.1% to 7.5%.
In BLS, we increase the midpoint by 2008 basis points due to the favorable impact of foreign currency.
Julia Wang: We continue to expect full-year enterprise margins to increase, with margins improving in both Diagnostics and BLS in 2025 versus 2024. For diagnostics, we expect a margin expansion in the second half of the year versus prior year. For BLS, we expect margins to be stronger in second half than first half, albeit overlapping a stronger prior year comparison. Our guidance range for just the EPS is $16.05 to $16.50. with an implied growth rate at the midpoint of 12%. As compared to our prior guidance, we have narrowed the range and raised the midpoint by approximately 23 cents. by receiving from both currency and strengthening our underlying business.
Speaker Change: and narrowed the growth rate to 6.1% to 7.5%
We continue to expect full year Enterprise margins to increase.
Speaker Change: With margins, improving in both Diagnostics and DLS in 2025 versus 2024.
Speaker Change: For Diagnostics, we expect the margin expansion in the second half of the Year versus prior year.
Speaker Change: For BLS, we expect margins to be stronger in second half than first, half our base overlapping, a stronger prior year comparison.
Speaker Change: Our guidance friends for just the EPS is 165 to $16.50.
With an implied growth rate at the midpoint of 12%.
Speaker Change: As compared to our prior guidance, we have narrowed the range and reached the midpoint by approximately 23 cents.
Julia Wang: Our free cash flow guidance range is $1.125 billion to $1.275 billion. We raised the midpoint by $25 million versus prior guidance. And due to normal seasonality, we expect to generate the majority of free cash flow in the second half of the year.
Speaker Change: By missing from both currency and strengthen our underlying businesses.
Our free cash flow. Guidance range is 1.125 million to 12275 million.
Speaker Change: We raised the midpoint by 25 million was inspired guidance.
Julia Wang: In closing, we continue to be encouraged by the strong performance across both business segments this quarter. The results reflect the effective execution of our strategy, the resilience of our operations, and the dedication of our teams across the organization. As we look ahead, we remain confident in our ability to deliver sustainable growth and long-term value for our shareholders.
Speaker Change: And due to normal seasonality, we expect to generate the majority of free cash flow in the second half of the year.
in closing, we continue to be encouraged by the strong performance across both business segments, this quarter
Speaker Change: The results, reflect the effective execution of our strategy, the resilience of our operations, and the dedication of our teams across the organization.
Operator: Operator, we will now take questions. Thank you. As a reminder, to ask a question, please press star 1-1 on your telephone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. Please stand by while we compile the Q&A roster.
Speaker Change: As we look ahead, we remain confident in our ability to deliver sustainable growth and long-term value for our shareholders.
Speaker Change: Operator. We will now take questions.
Speaker Change: Thank you.
Speaker Change: As a reminder to ask a question. Please press star 1, 1 on your telephone and wait for your name to be announced to withdraw your question. Please, press star 1 1, again please, stand by while we compile the Q&A roster.
Michael Cherny: And our first question comes from Michael Cherny of Lear and Partners. Your line is open. Good morning, Michael. Good morning everyone, congrats on a nice quarter. Maybe if I could just dive in a little bit on the volume dynamics and mix. I think everything is fairly. Broad based, Adam, is there anywhere?
Michael Cherney: And our first question comes from Michael Cherney of Ling Partners, your line is open.
Speaker Change: Good morning, Michael.
Adam Schechter: Please see the complete disclaimer at https://sites.google.com Growth. I'm just trying to parse through what exactly is going on in terms of driving the stability of... This year, given that I know there's a number of potential. the Regulatory side. Thank you. question for volumes for next year and beyond. So if we could parse. Yep, will do. And first of all, we appreciate the congratulations. It was a very strong quarter. And we saw the strength across both the diagnostics and the BLS business, which gives us a lot of momentum for the second half of the year as we go into next year.
Adam Schechter: Specific to your question on diagnostics, you know, the revenue was $2.7 billion, about 10% growth. But I think that the important thing is to look at the volume and where the growth came from. So about half of the 9% growth came from organic growth, and about the other half, 4.5% came from acquisitions. So then I look separately at what was volume. Overall volume was up about 5%, and then price mix was up 4%. And then I take it to organic volume. If you look at organic volume, it was up about 3.5%. And I think that shows the strength of the underlying growth that we have.
Speaker Change: Beyond. So if we can parse those 2 pieces together, that would be great. Yep. We'll do. And, uh, first of all, we appreciate the congratulations. It was a very strong quarter and we saw the strength across, both the Diagnostics. And the BLS business, which gives us a lot of momentum for the second half of the year as we go into next year. Specific to your question on uh, Diagnostics. You know, the the revenue was 2.7 billion dollars about 10% growth.
Speaker Change: um, but I think that the
Speaker Change: important thing is to look at the volume and where the growth came from. So about half of the 9% growth came from organic growth and about the other, half 4 and a half percent came from Acquisitions. So then I looked separately at what was volume overall volume was up in about 5% and then price mixed was up 4%.
Adam Schechter: Historically, that growth was 1% to 2%. So I do think we're seeing some accelerated growth. I think the accelerated growth is coming from several areas. One is the hospital, regional, local laboratory deals that we're doing are serving us well. Those areas are growing three to four times faster than the overall diagnostic market. And by focusing on those areas, you not only do well in those areas, but typically those patients have more severe disease. And with more severe disease, physicians typically look for more tests in order to understand the diseases. So therefore, the routine tests that we do actually grow faster when you have a focus on the specialty areas.
Speaker Change: And then I take it to organic volume. If you look at organic volume, it was up about 3.5% and I think that shows the strength of the underlying growth that we have historically, that growth was 1 to 2%. So I do think we're seeing some accelerated growth. I think the accelerated growth is coming from several areas. Uh, 1 is the hospital Regional local laboratory deals that we're doing are serving us. Well, it expands access in, uh, the hospitals and the surrounding geographies, but I think when you win those Hospital deals, the access in those geographies Works to your benefit and you actually gain share. The second thing is the
Speaker Change: Focus on our host, our Specialty Products in the areas of oncology, uh, neurology autoimmune disease, and neurology, those areas are growing.
Adam Schechter: And I think those two things are helping us accelerate our growth faster than you would expect, which gives us a lot of momentum going into 2026. Thank you.
Speaker Change: 3 to 4 times faster than the overall diagnostic market and by focusing on those areas you not only do well in those areas but typically those patients have more severe disease and with more severe disease, Physicians typically, look for more tests in order to understand the diseases. So therefore the routine tests that we do actually grow faster when you have a focus on the specialty areas and I think those 2 things are helping us accelerate our growth faster than you would expect. Which gives me, you know, a lot of um gives us a lot of momentum going into 2026.
Speaker Change: Thank you.
Ann Hynes: Our next question comes from Ann Hynes of Mizzou. Your line is open. Good morning, Ann. Good morning. Good morning, and thank you.
Speaker Change: Our next question comes from anaheim's of mujo. Your line is open.
Adam Schechter: I just want to ask about the legislative and regulatory outlook. Obviously, there's a lot of changes coming over the next few years. Maybe how we should think about PAM going into 2026. Do you think the risk has increased of those cuts coming back? And just on the legislative front, you know, as time goes by, it probably seems clear that the ACA subsidies are not being extended. How do you think those enhanced subsidies have positively impacted your business, and how should we view the risk in 2026? And just on the Medicaid side, can you remind us what LabCorp's Medicaid exposure and how changes to enrollment over the next few years could impact you?
Speaker Change: Morning and good morning. Good morning, and thank you. I just want to ask um about the legislative and Regulatory Outlook. Obviously there's a lot of changes coming over the next few years. Uh maybe how we should think about Pam, we're going into 2026. Do you think that risk has increased of those cuts coming back and just on the legislative front, you know, as time goes by it probably seems clear that the ACA subsidies are not being extended
Adam Schechter: Thanks. Yep. So let me start overall with how I think about the momentum we're going into the year next year with. And I think that the strength that you see in the quarter is going to serve us well. As I look at the legislative changes, and you look at the one beautiful bill, you look at PAMA and so forth, I look at them individually. So let me start with PAMA. PAMA, we're continuing to work with HLA, the trade organization, to try to get legislation approved that actually would be more apt to what they were trying to achieve with PAMA in the first place.
Speaker Change: How do you think those enhanced subsidies have positively impacted your business and how should we view the risk in 2026 and just on the Medicaid side? Could you remind us what? Um, Lab Corps, Medicaid exposure and how changes to enrollment over the next few years could impact you? Thanks.
Speaker Change: So, let me start overall.
With how I think about the momentum. We're going into that year next year with and I think that the strength that you see in the quarter is going to serve us. Well as I look at the legislative changes and look at the 1, be beautiful. Bill you look at Palma and so forth. I look at them individually. So let me start with Palma.
Adam Schechter: And we're going to continue to work on a legislative solution. If that doesn't happen, we'll continue to seek ways to see if it can be delayed again so that we can get appropriate legislation approved, to which we have very strong support from both Democrats and Republicans. If the delay doesn't occur, then we could also work to see, is there a way to ensure that the appropriate data is available to help calculate PAMA in a way which it was intended to be calculated, meaning that you need more data than just some of the laboratories. You need a lot of the hospital laboratories to get all the data you need.
Speaker Change: Uh Palma we continuing to work with acla the Trade Organization to try to get legislation approved that actually would be more apt to what they were trying to achieve with Palma in the first place. And we're going to continue to work on the legislative solution.
Speaker Change: If that doesn't happen, we'll continue to seek ways to see if it can be delayed again. So that we can get appropriate legislation approved of which we have very strong support for both Democrats and Republicans.
Adam Schechter: All three of those things are things that we'll be working on as we go through this year. In my base case, I've always said, assume PAMA comes next year, and I've said that for the last five years now, and we build our base case that it's coming because we don't know if any of these other strategies will actually occur. If PAMA does come next year, it will be about a $100 million impact, top and bottom line, of which we'd work hard to offset as much of that as we possibly could through things like LaunchPad and even going further than what we've done with LaunchPad.
Speaker Change: If the delay doesn't occur, then we could also work to see, is there a way to ensure that the appropriate data is available to help calculate Pamela in a way which it was intended to be calculated, meaning that you need more data than just, some of the Laboratories you need. A lot of the hospital Laboratories to get all the data you need.
Adam Schechter: Separate and distinct from that, when I think about other legislation, I would say, in broad terms, we see some tailwinds, and we see some headwinds, but if you look at it all together, and you look at all the different scenarios, for our business, we think it's manageable. First of all, if you look at lab testing, it's a very small fraction of US health care spend. But it's an essential tool, and it's used in almost every health care decision. So people realize the importance of laboratory testing. If you think about the legislation, I think it's going to be hard on some of our customers like hospitals.
Speaker Change: They could through things like Launchpad and even going further than what we've done with LaunchPad.
Speaker Change: Separate and distinct from that. When I think about other legislation I, I would say in Broad terms, we see some Tailwind
Speaker Change: and we see some headwinds but if you look at it all together and you look at all the different scenarios for our business, we think it's manageable,
Speaker Change: First of all, if you look at lab testing, it's a very small fraction of us Healthcare spend, but it's in the essential tool and it's used in almost every Healthcare decision. So people, realize the importance of Laboratory Testing,
Speaker Change: if you think about the legislation,
Adam Schechter: and it could have hospitals work with us faster and want to do even more deals with us in terms of outreach business and also running Your hospital, hospital laboratory. In addition to that, if you look at the health care exchange and expiration of the tax credits, there could be a negative impact, and we've measured that to be as high as 30 basis points.
Speaker Change: I think it's going to be harder in some of our customers like hospitals.
Speaker Change: And it could have hospitals work with us faster and want to do even more deals with us in terms of Outreach business and also running.
Speaker Change: Your hospital hospital. Laboratories
Adam Schechter: If you look at Medicaid, I don't think anything is going to really happen until 2028. And the key is going to be, do people find insurance through other ways, through states or spouses that might have insurance? To me, the key is if people have insurance, we find ways to be successful. When there's a very large group of people that could become uninsured, that's where we get concerned. I don't think that's likely. I don't think it's very likely in the United States that you'll have a very big group of people automatically become uninsured in a specific period of time.
In addition to that, if you look at the healthcare exchange and expiration of the tax credits, there could be a negative impact and we've measured that to be as high as 30 basis points.
Speaker Change: If you look at Medicaid, I don't think anything is going to really happen until 2028, and the key is going to be, do people find insurance through other ways to States or, uh, spouses that might have insurance. I to me, the key is if people have insurance, we find ways to be successful. When there's a very large group of people that could become uninsured. That's where we get concerned. I don't think.
Adam Schechter: So net-net, boiling it all down, Pam and I put aside, we'll do everything we can to either change the legislation, delay or offset as much as we can. The other legislative things are manageable when you look at the impact net.
Adam Schechter: The only thing I would add is we do not expect the one big beautiful bill to have a material impact on our overall effective tax rate. We continue to expect our tax rate to be approximately 23% for full year 2025 and beyond.
Speaker Change: I think that's likely, I don't think it's very likely in the United States that you'll have a very big group of people automatically become uninsured. Uh, in a specific period of time. So net, net, boiling it all down. Pam, I put aside, we'll do everything we can to either change the legislation delay or offset as much as we can. The other legislative things are manageable, when you look at the impact net, net,
Ann Hynes: Great, thank you. Thank you.
Speaker Change: The only thing I would add is we do not expect the 1, big beautiful Bill to have a material impact on our overall effective tax rate. We continue to expect our tax rate to be approximately 23% for 2 full year 2025 and Beyond.
Speaker Change: Great. Thank you.
Thank you.
Kevin Caliendo: Our next question comes from Kevin Caliendo of UBS. Your line is open. Morning, Kevin. Good morning. Congrats. Really, really impressive performance, guys.
Speaker Change: Our next question comes from. Kevin kiondo of UBS. Your line is open.
Speaker Change: Morning. Kevin.
Adam Schechter: Can I ask about the community health deal a little bit? We didn't get a lot of details from you around it. I understand it's not going to close till 4Q, and so the impact this year isn't great. But from an absolute size perspective, $195 million is meaningful. Is this deal expected to be accretive in the first 12 months, flat? Can you talk a little bit about maybe the mix of the business or the profitability of that? Does it need to be repriced? As much detail as you can provide, because obviously it's going to be a somewhat interesting piece of the bridge when we think about 2022.
Adam Schechter: Yeah, no, absolutely, Kevin. First thing I say is that if you recall, we actually increased the range that we thought that inorganic growth would happen. It used to be 1% to 2%. Now we say 1.5% to 2.5%. A lot of that is incorporated because of the hospital deals that we're doing, of which this is one. If I look at the deal and the hospital deals, our bar is high. We want them to be accretive in the first year, return a cost of capital in a couple years, and be something that we know how to do and integrate with a good partner we can work with.
Adam Schechter: And I would say CHS deal, it meets all those criteria. Obviously, it's going to depend on how fast we can close and so forth to see what the impact will be, but we're going to try to work with them to close as quickly as we possibly can. As you said, we paid $195 million of cash, and I think it's going to prove to be another really good hospital deal for us. It's the outreach business, which is typically the higher margin business. It's the hospital laboratory. When we run those laboratories, you have the lower margin, albeit a high return on cost of capital business.
Kevin Caliendo: So this is outreach, which actually is better for margins. Got it. Thank you.
Patrick Donnelly: Our next question comes from Patrick Donnelly of City. Your line is open. Good morning, Patrick. Hey, good morning. Thanks for taking the questions. Maybe one on the BLS segment, you know, nice performance there. You know, nice to see the bookings pick up as well. Can you just talk about what you saw in the quarter, I guess, both Central Lab and then particularly the early development? It looks like it picked up a little bit of momentum as the quarter went. You've heard from the CRO group this week, quite positive in terms of some of those prints.
Julia Wang: So did you see improvement as the quarter went? Can you just talk about some of those customer conversations? I know if we rewind three or six months, there's a lot of concern about this business. It seems like it's turning the corner a bit, so we'd love to pull the curtain back a little bit there. What you saw as the quarter went, and then again, expectations going forward just given the bookings. Thank you.
Julia Wang: Sure. So I'll start off with, you know, the BLS revenue was 11% increase year over year, it was 8% if you look at it in constant currency. And we had good growth for both businesses. We had 8% or 4% constant currency for our central labs and 20 or 18 for ED.
Julia Wang: But let me break that apart for you and then I want to talk about the book to Bill. If you look at the ED, it was a relatively easy compare to the prior year, which accelerated the growth. If you look at fourth quarter of this year, it's going to be a much more difficult compare for ED than the second quarter was. The other thing is, when studies start, you tend to get a bolus of payment at the start of a study. So we had some additional study starts in the quarter. But putting all that aside, ED is back to growth.
Julia Wang: And we expected to grow for the full year in the mid single digits, which is a good place for us to be. And if you look at ED, what I look at is our number of RFPs that come in, which remain consistent. I look at our win rate, which remains consistent. And the thing that I look at most carefully now is whether the trials start on time. And that's something we're going to continue to look at very closely. But, you know, when I look at the second quarter, the win rate, the RFPs, and the timing of studies look good.
Julia Wang: If I look at Central Laboratory, that's where I focus a lot on book to bill. If you look at the whole business, BLS, the book to bill is very strong. And it was a 1.1. If you look at the trailing 12-month book to bill, which is a very good place to be. I've always said you have to be above 1. We're at 1.1. That was driven by a couple of large trials that we won in the Central Laboratories. The good thing about large trials are they give you fuel for a longer period of time. So I feel really good about the book to bill that we posted.
Julia Wang: And I think it gives us momentum when you think about the Central Laboratory business moving into the future.
Julia Wang: Great, thank you.
Lisa Gill: Thank you. And our next question comes from Lisa Gill of J.P. Morgan. Your line is open. Good morning, Lisa. Good morning, Adam and Julia. Thank you for taking my question.
Adam Schechter: Adam, can you maybe just discuss anything on the horizon around managed care contracting? Do you have any large contracts that are up for renewal going into 26? Any changes around how you're contracting with managed care? Yes, so as I look at our managed care contracts, they typically vary length anywhere from three years to five years. So each year we're renewing maybe 20, 25 percent of our contracts. You know, we continue to see unit price relatively flat, which is a good place to be. I'm confident that we've got the renewals that we need for this year, and I feel good those are secured.
Speaker Change: We continue to see unit price relatively flat, which is a good place to be I'm confident that we've got the renewals that we need for this year and I feel good those are secured the reasonable terms are reasonable rates the supportive of our near long term guidance and as I look into the future I feel confident that we have very good relationships.
Adam Schechter: They're reasonable terms and reasonable rates. They're supportive of our near long-term guidance. And as I look into the future, I feel confident that we have very good relationships. And one of the things that helps is the hospital deals that you do actually causes the rates to go down for the payers. And I think the more hospital deals we do, the more we're able to talk to payers about the benefit that we're providing to them above and beyond just talking about the cost of our individual tests. So I think that has served us well in those discussions, but I feel very good about our position.
Ships and one of the things that helps is the hospital deals that you do actually causes the rates to go down for the payers and I think the more hospital deals we do the more we're able to talk to payers about the benefits that we're providing to them above and beyond just talking about the cost of our individual test. So I think that is.
Speaker Change: Best well in those discussions, but I feel very good about our position.
Lisa Gill: Thank you.
Speaker Change: Thank you.
Speaker Change: Thank you.
Jack Meehan: And our next question comes from Jack Meehan of Nephron Research, your line is open. Morning, Jack. Good morning, Adam. Good morning, Julia. So we're almost at the one year anniversary of the In Vitae deal.
Speaker Change: And our next question comes from Jack Meehan of Nephron Research. Your line is open.
Speaker Change: Good morning, Jack.
Jack Meehan: Good morning, Adam Good morning, Julien.
Jack Meehan: So we're almost at the one year anniversary of the <unk> tie deal wanting to hear just how you feel like revenue is tracking there how competitive dynamics are in the market and then finally just confidence in getting the business profitable.
Adam Schechter: Wanted to hear just how you feel like revenue is tracking there, how competitive dynamics are in the market, and then finally, just confidence in getting the business profitable. So I am very confident in our position with Amita. The integration is going extremely well. I'm confident in the revenue growth of 10% yearly, and I'm also confident in it being slightly accretive for the full year. The team is doing a great job. We've improved the customer experience. The customers are excited. So, you know, everything's right on track, and I feel very good about where we are in the position.
Jack Meehan: So I am very confident in.
Jack Meehan: Up to this sort of rethink that integration is going extremely well I'm confident in the revenue growth of 10% yearly and I'm also confident in it being slightly accretive for the full year.
Jack Meehan: Team is doing a great job.
Jack Meehan: We've improved the customer experience.
Jack Meehan: Customers are excited.
Jack Meehan: So everything is right on track and I feel very good about where we are in a position.
Julia Wang: It's a great add to the offerings that we had for both women's health and specialty areas, and our sales reps are excited to have it as part of us, but also the physicians are excited that we now have that offering as part of LabCorp.
Jack Meehan: Great add to the offerings that we had for both women's health and specialty areas.
Jack Meehan: Our sales reps are excited to have it as part of us but also the.
Jack Meehan: The physicians are excited that we now have that offering as part of Labcorp.
Julia Wang: Hi, Jack, maybe I can provide some additional color as a release to margin overall inclusive of Inviti. A record that we are very encouraged by our strong performance in the second quarter, whereby we grew top line by almost double digits with 20 basis point of margin expansion, despite a 30 basis point headwind from Inviti. This enterprise margin expansion in the quarter was actually supported by the improvements in both business segments. Given the first half results, we actually expect to drive margin expansion in the second half at a level that will enable us to deliver full-year margin ratio growth, once again supported by both segments.
Jack Meehan: Hi, Jack maybe I can provide some additional color as it relates to margin overall process of in Vaca <unk>. We are very encouraged by our strong performance in the second quarter, whereby we will top line by almost double digit with 20 basis point of margin expansion. Despite eight.
Jack Meehan: Eight basis point headwind from MVP.
Jack Meehan: Enterprise margin expansion in the quarter with actually supported by improvements in both business segments.
Jack Meehan: Given the first half results, we actually expect to July of Martin's passing in the second half at a level that will enable us to give any more full year margin ratio growth once again supported by both segments.
Julia Wang: So when you think about the cadence for diagnostics, we tend to see the margins being the highest in the second quarter, and then sequentially moderating in Q3 versus Q2, and then Q4 versus Q3. For the BLS segment, we also expect margins to be up in the second half versus prior year. However, not necessarily at the pace that we saw in Q1 or Q2, considering we had a significant margin progression throughout last year. So overall, I would say that as an organization, we are highly focused on continuing to deliver strong top-line growth while driving margin expansion through opportunities.
Jack Meehan: So when you think about the cadence all diagnostics, we tend to see the margins being the highest in the second of horsepower and ask the question a moderating in Q3, what does Q2 and think you'll fall versus Q3.
Jack Meehan: So the BLS settlement, we also expect to be operating the second half of what was prior year. However, not.
Jack Meehan: Not necessarily at the pace that we saw in Q1, okay to kind of see the one we had a sneaking Nathan Martin for questions and well off last year. So overall I would say that as an organization. We're highly focused all continuing casino was solid topline growth, while driving margins passion for operating efficiencies.
Jack Meehan: Yeah.
Julia Wang: Thank you.
Jack Meehan: Thank you.
Jack Meehan: Okay.
Elizabeth Anderson: And our next question comes from Elizabeth Anderson of Evercore ISI. Your line is open. Good morning, Elizabeth. Hi, guys. Good morning. Thanks so much for the question and congrats.
Speaker Change: And our next question comes from Lucid with Anderson of Evercore ISI. Your line is open.
Speaker Change: Morning, Elizabeth Hi, guys. Good morning, Thanks, so much for the question and congrats.
Elizabeth Anderson: I was wondering if you could maybe expand a little bit more on your BLS commentary, if you have any comments on sort of biotech versus pharma or sort of pockets of strength that you're seeing in general, though, obviously, with the particular adjunct.
Speaker Change: I was wondering if you could maybe expand a little bit more on your BLS commentary if you have any comment.
Speaker Change: Okay versus pharma or sort of pockets of strength that youre seeing in general, though I would say with the book to bill of that than it is.
Speaker Change: Its decently widespread.
Julia Wang: I was wondering if you can just remind us, as we think about the impact of FX on the business, I think you guys called it out very clearly on the revenue line, but just sort of remind us as we go down the P&L how we think about the change in FX on the EPS line. Yep, Elizabeth, I'll talk about BLS. I'll ask Julia to talk a little bit about the impact of FX. If you look at BLS, we saw strength in both businesses in the quarter, and we expect both businesses to grow for the full year in the mid-single digits.
Speaker Change: And then two I was wondering if you can just remind us as we think about the impact of FX on the business I think we called it out that you guys called out obviously very quickly on the revenue line, but just sort of remind us as we go down the P&L.
Speaker Change: How we think about the change in FX.
Speaker Change: The EPS line. Thank you very much Elizabeth I'll talk about Pls I'll ask Julia to talk a little bit about the impact of FX. If you look at Pls.
Speaker Change: We saw strength in both businesses in the quarter.
Speaker Change: We expect both businesses to grow for the full year in the mid single digits. If I looked at CLS CLS is heavily skewed towards larger farmer.
Adam Schechter: If I look at CLS, CLS is heavily skewed towards larger farmer later stage trials, Phase 3 trials. And there we had a couple big wins. I feel good about that. I think under all circumstances, farmers are going to continue to support their Phase 3 pipelines, and that's a strength for us. As I look at our early development, that is mostly smaller biotechnology companies, and we saw a good number of RFPs and win rate there. But that's something we're going to watch very closely to ensure that the funding environment remains favorable, to ensure that they get the information they need to start studies on time as they move forward.
Speaker Change: Later stage trials phase III trials and there we had a couple of big wins I feel good about that I think under all circumstances farmers are going to continue to support their phase III pipelines and that's a strength for us as I looked at our early development that is mostly smaller biotechnology companies and we.
Speaker Change: Good number of Rfps or win rates, there, but that's something we're going to watch very closely to ensure that the funding environment remains favorable to ensure that they get the information they need to start studies on time as they move forward. So that one I think we have to watch more closely than the CLS, where I feel more confident based on.
Adam Schechter: So that one, I think we have to watch more closely than the CLS, where I feel more confident based upon the later stage trials in the larger companies. With all that said, ED is back to growth.
Speaker Change: Kind of later stage trials in larger companies with all that said <unk> is back to growth. It's important to note that the fourth quarter's going to be a very tough compare versus fourth quarter of last year, but if you look at the full year, we expect it to grow in the mid single digits.
Adam Schechter: It's important to note that the fourth quarter is going to be a very tough compare versus fourth quarter of last year. But if you look at the full year, we expect it to grow in the mid-single digits.
Julia Wang: Hi, Elizabeth. Let me comment a bit on the FX impact. We clearly are operating in a very dynamic FX environment. If you step back and look at the composition of our businesses, obviously the diagnostic side accounts for over 75% of our revenue, but it's primarily based in the United States. And the BLS side of the business is where we're more global in our footprint, and therefore having FX exposure. The economy says that we have meaningful exposure too for BLS, including the Swiss franc and the British pound. If you just look at the Q2 enterprise revenue growth of the 9.5% year-over-year, it did include a favorable currency impact of 60 basis points due to BLS.
Speaker Change: Hi, good as of Wednesday may comment a bit on the FX impact we clear now operating in a very dynamic FX environment.
Speaker Change: If you step back and look at the compensation of our businesses' of vis vis the diagnostics side across the over 75% of our revenue, but its primarily based in the United States and Libya at the side of the business is where we're more global footprint and therefore, having a FX exposure.
Speaker Change: On the comments is that we have meaningful exposure to for <unk> include the Swiss franc and the British pound.
Speaker Change: Just look at the Q2 enterprise revenue growth of the nine 5% year over year.
Speaker Change: These include a favorable currency impact after six to eight basis points due to B O S.
Julia Wang: And then when you move to look at the full-year guide, which is provided at the midpoint, the enterprise revenue guide is 70 basis points. And we are expecting an FX impact based on the rate at the end of Q2 in that magnitude. Thank you.
Speaker Change: Then when you move to look at the full year guide that we just provided at the meet point the enterprise revenue guide.
Speaker Change: At the 70 basis points, and we are expecting a FX impact based on the rate at the end of Q2 in that magnitude.
Speaker Change: Okay.
Speaker Change: Okay.
Speaker Change: Thank you.
Speaker Change: Okay.
Andrew Brackmann: And our next question comes from Andrew Brackmann of William Blair. Your line is open. Hi Adam, hi Julia, hi Kristen. Thanks for taking the questions. Maybe just on pricing, I think you called out organic pricing up in the quarter. Can you maybe just peel that back a bit for us just in terms of the key drivers there? And then I guess how should we think about that trending forward, especially as the mix continues to shift towards those specialty tests?
Speaker Change: And our next question comes from Andrew Brachman of William Blair. Your line is open.
Andrew Brachman: Hi, Adam Hi, Julien Hi, Christian Thanks for taking the questions.
Speaker Change: Maybe just on pricing I think you'd called out organic pricing up in the quarter can you, maybe just peel that back a bit for us just in terms of the key drivers there and then I guess, how should we think about that trending forward, especially as the mix continues to shift towards the specialty tests. Thanks.
Adam Schechter: Thanks. Okay, so if you look at pricing, you know, I look at a few things. I look at our test per accession, and our test per accession continues to show growth. And, you know, I think that that's occurring. If you go historically, I said that I thought that that was a post-COVID acceleration because people didn't get diagnosed during COVID. I actually think it's more than that. I think that there's an aging population. I think there's more severity of disease. So, I think people are actually doing more test per accession. We also include in that the lab The second thing I think that's helping to drive that is the specialty growth.
Andrew Brachman: Okay.
Andrew Brachman: So if you look at pricing I looked at a few things I look at our test per accession and our test per accession continues to show growth.
Andrew Brachman: And I think that that's occurred.
Andrew Brachman: Historically, Ive said that I thought that that was a post COVID-19.
Andrew Brachman: Acceleration because people didnt get diagnosed during COVID-19 I actually think it's more than that I think that there is amazing population I think theres more severity of disease. So I think people are actually doing more.
Andrew Brachman: Test for exception. We also include in that.
Andrew Brachman: That management and the second thing I think that's helping to drive that is the specialty growth. So we are seeing asymptotic continuing increase in our specialty testing vis vis the routine testing and I think that also helps with the price per accession.
Julia Wang: So we are seeing asymptotic continuing increase in our specialty testing vis-a-vis the routine testing. And I think that also helps with the price per accession. The only thing I would also compliment is from a unit price perspective, we continue to sit as relatively flat, and therefore, when you think about the price-max impact, it's really been benefiting from the impact of MIPS.
Speaker Change: The only thing I would also complement is from a unit price perspective, we continue to see as relatively flat and therefore, when you think about the price mix. The impact is really be beneficial without the impact of met and as Adam already shared the pay contributors.
Julia Wang: And as Adam already shared, the key contributors, once again, are the gradual, yet consistent growth in tax procession, as well as net management. Thank you.
Andrew Brachman: With that I'll be glad.
Andrew Brachman: Gradually get to consistent growth impacted plus session at wealth management appointments.
Andrew Brachman: Yeah.
Andrew Brachman: Thank you.
Andrew Brachman: Yes.
Tycho Peterson: And our next question comes from Tycho Peterson of Jeffries. Your line is open. Good morning, Tycho. Good morning. Congrats on the quarter. So I just want to throw on some of the new content launches, starting with Alzheimer's. Curious how you're sizing the opportunity for PTAL 217 beta amyloid and any market development that needs to happen there. And then the follow-up is on MRD with plasma detect. How has early adoption been? Any synergies you can point to with PGDX for therapy selection? And how do you think about kind of broader menu build-out for MRD? Thanks.
Speaker Change: And our next question comes from Tycho Peterson of Jefferies. Your line is open.
Tycho Peterson: Hey, good morning, Congrats on the quarter. So just wanted to probe on some of the new.
Tycho Peterson: Content launches, starting with Alzheimer's curious, how you're sizing the opportunity for <unk> to 17 beta amyloid in any market development that needs to happen. There and then the follow up is on MRV with plasma detect.
Tycho Peterson: How is the early adoption been any synergies you can point to with PDD extra therapy selection and how do you think about kind of a broader menu buildout for MRV.
Adam Schechter: Yeah, absolutely, I think that's a very important question as you think about specialty and where we're going. The first thing I'd say, though, Tygo, is that when I think about the specialty testing, I don't think about the individual test alone, because the patient that gets that test is also going to get a whole host of other tests. So if you have somebody that's going to get an MRD test, they're probably going to get TBCs, WBCs, ALTs, ALTs, and a whole host of other things to see and measure their organs as well as their minimal residual disease.
Tycho Peterson: Thanks.
Speaker Change: Yeah, absolutely I think Thats, a very important question as you think about specialty and where we're going.
Speaker Change: The first thing I'd say, though tiger is that when I think about the specialty testing I don't think about the individual test alone.
Speaker Change: The patient that gets that test is also going to get a whole host of other tests. So we have somebody that's going to get.
Speaker Change: MRV tests are probably going to get Cvc's, wbc's, alc's, ALC and a whole host of other things to see and measure their organs as well as their minimum residual disease. So to me having the broad.
Adam Schechter: So to me, having the broad range of tests is as important as having the most important new tests. So we don't break out the new tests, because none of them individually do I think is going to be that meaningful to change kind of the trajectory or be that material. But when you look at it as a whole, I think it actually is very material. Two reasons. One is we are seeing a shift in mix towards specialty testing, but as important the spillover from other tests for those specialty patients. As I think about oncology, I think it's important because oncology testing for precision testing is growing, and it's going to continue to grow, and there's going to be more and more and we continue to look at things like OmniSeq and PGDX and Invitae to say, how can we add to that portfolio so we have a full complement of what an oncologist would want.
Speaker Change: Our range of pass is as important as having the most important new fabs. So we don't break out the new test because none of them individually do I think theres going to be that meaningful to change kind of the trajectory would be that material, but when you look at it as a whole I think it actually is very material two reasons one.
Speaker Change: We are seeing a shift in mix towards specialty testing, but as importantly, the spillover from other test for those specialty patients as I think about oncology.
Speaker Change: I think it's important because oncology testing for precision testing is growing and it's going to continue to grow and it's going to be more and more products launched in those areas from pharma and we continue to look at things like omni seek in <unk> and in deep day to say, how can we add to that portfolio. So we have a full complement of water.
Adam Schechter: In addition to that, we're open to licensing other tests, to bringing other tests that others have developed to market, because once again, it's not about the individual test, it's about having the broadest range of tests. And I would say the same thing for Alzheimer's disease. Okay, thank you. Thank you.
Speaker Change: And caller just with one.
Speaker Change: To that we are open to licensing the other tests to bringing other tests that others have developed to market because once again, it's not about the individual test it's about having the broadest range of tests and I would say the same thing for <unk> disease.
Speaker Change: Okay. Thank you.
Speaker Change: Thank you.
David Westenberg: And our next question comes from David Westenberg of Piper Sandler. Your line is open. Hi. Good morning, Adam. Thanks for taking the question and congrats, particularly impressive in that operating leverage.
Speaker Change: And our next question comes from David Westenburg of Piper Sandler Your line is open.
Speaker Change: Hi.
Speaker Change: Good morning, Adam Thanks for taking the question and congrats.
Speaker Change: Particularly impressive in that operating leverage.
Adam Schechter: I wanted to jump on some of Tycho's questions and focus on the oncology section. You know, you launched a few new products. You're getting CGP, liquid, MRD, etc. How do you see that market shaking out over the next few years? I mean, currently liquid and CGP, NGS tend to be fairly oligopolistic. Do you see that market evolving to something where, you know, your reach, your breadth might have a bigger impact? Is that markets become a little bit more commoditized? Maybe that's not the best word there. But anyway, you can think about how that shakes up.
Speaker Change: I wanted to.
Speaker Change: Jump on some tyco's question, but I'd focus on.
On the oncology section you launched a few new products Youre getting CGP liquid Mardi et cetera, how do you see that market shaking out over the next few years I mean currently liquid and CGP Ngls tend to be fairly oligopolistic do.
Speaker Change: Do you see that market evolving to something where youre reach Nebraska might have a bigger impact as that market has become a little bit more commoditize.
Speaker Change: Maybe that's not the best word there, but any way you can think of that how that shakes out and then I. Just wanted a clarification you mentioned three to four or 4% Army sorry four acts.
Adam Schechter: And then I just wanted the clarification. You mentioned 3 to 4 or 4 percent, I mean, sorry, 4x esoteric growth versus a regular test growth. Is that, has that been accelerating of late or is that just, you know, the constant steady state? Just as a clarification. Thank you. Yes. So the 3 to 4 percent was for the esoterics in four areas I mentioned, oncology, neurology, autoimmune and women's health. And that's been for quite some time now. So those areas have just been growing faster than the other diagnostic or non-diagnostic area, 3 to 4 times. With regard to oncology and MRD, I think you want a full portfolio.
Speaker Change: So current growth versus.
Speaker Change: Our regular test growth is that has that been accelerating.
Speaker Change: Of late or is that just the constant steady state just said with clarification. Thank you, yes, so the 3% to 4% was for the esoteric.
Speaker Change: Four areas I mentioned oncology neurology autoimmune.
Speaker Change: Women's health and that's been for quite some time now so those areas have just been growing faster than the other diagnostic underlying diagnostic area three to four times with regard to oncology of them or do you think you want a full portfolio.
Adam Schechter: I want tissue capabilities, but I also want liquid capabilities. When I think about liquid capabilities, there's three things I think about. Screening, and the ability to screen patients for cancer. I think that is going to be important, but it's going to take a very long time to develop that market and to gain reimbursement, and I think it'll be, you know, very large trials and take some time. Then I think about therapy selection, and that's an area that we are heavily invested in, that we're going to be a leader in, because I think that as physicians are thinking about what therapy they want to use, having both tissue as well as liquid could be very helpful there.
Speaker Change: Tissue capabilities.
Speaker Change: Capabilities, but also our liquid capabilities. When you think about liquid capabilities. There's three things I think about one is.
Screening and the ability to screen patients for cancer I think that is going to be important, but it's going to take a very long time to develop that market and to gain reimbursement and I think there'll be very large trials and it takes some time, then I think about therapy selection and that's an area that we are heavily invested.
Speaker Change: And we're going to be a leader in because I think that as physicians are thinking about what therapy. They want to use having both tissue as well as liquid could be very helpful. There and then I think about minimal residual disease. After their cancer has been treated deemed cured how do you monitor them overtime that one I think will be reimbursed over.
Adam Schechter: And then I think about minimal residual disease, after their cancer has been treated, they're deemed cured, how do you monitor them over time? That one I think will be reimbursed over time, particularly as we have the data to support that we can actually identify those early that have recurrence, and we'd like to be a leader there. So I want to be a leader in therapy selection, I want to be a leader in the minimal residual disease. I'm willing to be more of a follower when it comes to screening, because it's going to take so long, and it's going to take a lot of money to develop over time.
Speaker Change: With time, particularly as we have the data to support that we can actually identify those early that have recurrent and we'd like to be a leader there. So I want to be a leader in therapy selection and they want to be a leader in the minimal residual disease I'm willing to be more of a follower when it comes to screening because it's going to take so long and it's going to take a lot of money to develop over time.
Adam Schechter: But when you put it all together, if you are an oncologist, then you can come to one laboratory to get your tissue, your liquid, and all the other tests that you might need for your oncology patient, versus having to go to two labs or three labs with different reports, different warning systems, not have as convenient sites for blood collection and turnarounds. I think over time, our size, our scale, combined with our scientific expertise, will be a competitive advantage.
But when you put it all together if you were an oncologist and you can come to one laboratory to get your tissue illiquid and all the other tests that you might be for your oncology patient versus having to go to two apps for three labs with different reports different ordering systems not haven't.
Speaker Change: Vineyard sites for blood collection.
Speaker Change: Turnarounds I think over time, our size our scale combined with our scientific expertise will be a competitive advantage.
Speaker Change: Sure.
Luke Sergott: Thank you.
Speaker Change: Thank you.
Julia Wang: And our next question comes from Luke Sergott of Barclays. Your line is open. Morning, Luke. Morning. Thank you for the questions here. I just want to follow up on the BLS strength and the bookings commentary that you guys have been giving, and also the RFP. So anything that you can dig in on from a therapy indication, we've been hearing a lot about metabolic disease from the other CROs. And so I want to know about how the funnel's been filling for you guys. And if there's any, like. Change in the trends from either the therapy regarding metabolic, et cetera, or from biotechs where you're seeing all of a sudden pent-up demand start flowing through from mid-sized biotech, or is this coming from the pre-revenue biotech where the funding has just been really tough over the last...
Speaker Change: And our next question comes from Larry <unk>.
Speaker Change: <unk> of Barclays. Your line is open.
Speaker Change: Good.
Speaker Change: Good morning. Thank you for the questions here I just wanted to follow up on the BLS strength in the bookings commentary that you guys have been giving.
Speaker Change: And also the RFP. So anything that you can dig in on from like a therapy indication we've been hearing a lot about metabolic disease from the other <unk> and so I wanted to know about how the funnel has been filling for you guys and if there's any like.
Speaker Change: Change in the trends from the either the therapy regarding like metabolic et cetera, or like from biotechs, where youre seeing all of a sudden pent up demand start flowing through from midsize biotech or.
Speaker Change: Or is this coming from the pre revenue biotech where the funding has just been really really tough over the last.
Adam Schechter: Yeah, so let me break apart the two businesses, and I'll start with CLS. CLS has been large pharma. With a lot of large pharma, we have either service agreements, MSAs with them, and depending on which pharma company and what their pipeline's like, that's where our business goes, and we kind of follow the business of our largest customers. So, you know, just like you would see in a marketplace, as you see more trials that are occurring in certain areas, you can assume that we would be strong in those areas. Obviously, oncology, neurology, metabolic are still the largest and fastest growing areas for us.
Speaker Change: A few years.
Speaker Change: So let me break apart the two businesses and I'll start with the CLS CLS has been large pharma with a lot of large pharma, we have either service agreements msas with them and depending on which pharma company and what their pipeline looks like.
Speaker Change: Thats, where our business goes when we kind of followed the business of our largest customers. So you know.
Speaker Change: Just like you were seeing in the marketplace as you see more trials that are occurring with certain areas. You can assume that we would be strong in those areas, obviously oncology and neurology metabolic are still the largest and fastest.
Adam Schechter: If you then go to the early development business, and the central lab is more big pharma, big biotech. If you go to early development business, you know, there it's mostly smaller companies. That's where you'll see a lot of cell and gene therapies for some certain rare diseases. When it comes to large pharma, a lot of them do their own early development, so it's mostly individual companies on individual compounds or companies that are looking to develop multiple compounds in the same area. There, it would be more in the esoteric areas.
Speaker Change: Fastest growing areas for us if you then go to the early development business.
Speaker Change: The Central lab is more big pharma Big biotech if you go to early development business. There, it's mostly smaller companies, that's where you'll see a lot of selling gene therapies for some certain rare diseases. When it comes to large pharma a lot of them do their own early development. So it's mostly individual companies or individual comp.
Speaker Change: And those are companies that are looking to develop multiple compounds in the same area. There it would be more in the esoteric areas.
Julia Wang: All right. Thanks. Thank you.
Speaker Change: Okay, great. Thanks.
Speaker Change: Okay.
Speaker Change: Thank you.
Speaker Change: Yeah.
Erin Wright: And our next question comes from Erin Wright of Morgan Stanley. Your line is open. Good morning, Erin. Great. Good morning. Thanks for taking the question.
Speaker Change: And our next question comes from Erin Wright of Morgan Stanley. Your line is open.
Erin Wright: Morning, Eric.
Erin Wright: Good morning, Thanks for taking the question. So just more of a bigger picture question just on utilization trends in the <unk>.
Erin Wright: So just more of a bigger picture question just on utilization trends in the diagnostic segment. And you obviously increased your guidance. You mentioned the strength across utilization. And we're obviously hearing it from managed care companies and others. But what's embedded in your guidance as we head into the second quarter? Is there any normalization in trend, or just a continuation of the same? Or are you seeing this accelerate? And then just how durable you're thinking these trends can be? I mean, excluding some of the policy dynamics that are some unknowns. But outside of that, this underlying kind of base utilization strength that we're seeing and the sustainability of that, if you could comment on it.
Erin Wright: Diagnostics sector.
Erin Wright: Obviously increased your guidance you mentioned the strength the cross utilization.
Erin Wright: We're obviously hearing it from managed care companies and others, but what's embedded in your guidance as we head into the second quarter or is there any normalization in trend or just a continuation of the same or are you seeing this accelerate and then just how durable youre thinking these trends can be I mean, excluding some of the policy dynamics that are similar.
Erin Wright: Loans, but outside of that like this underlying kind of base utilization strength that we're seeing in the sustainability of that if you could comment on that.
Julia Wang: Thanks. Sure. So, you know, the volumes continue to be very healthy and they're tracking in line with their expectations. If you look at the midpoint of the Diagnostics Revenue Guide, it's seven and a half percent, and we assume about half of the revenue growth will come from organic growth and the rest comes from the annualization of our acquisitions. If you look at the organic growth, we expect a volume mix contribution of three to one, just like we saw in the second quarter. So, you know, three for volume, one for mix. When we think about some of the factors that we think are driving that, and that will continue to support the utilization as we go into the future, there's an aging population, there's high rates of disease prevalence, and we continue to see improvements in advanced diagnostics in the specialty testing areas, including things like companion diagnostics.
Erin Wright: Thanks.
Erin Wright: Sure.
Speaker Change: So the volumes continue to be very healthy and they are tracking in line with our expectations. If you look at the mid point of the diagnostics revenue guide at seven 5% and we assume about half of the revenue growth will come from organic growth and the rest comes from the amortization of our acquisitions. If you look at the organic growth we expect.
Speaker Change: So your mix contribution of three to one just like we saw in the second quarter. So three for volume one for mix. When we think about some of the factors that we think are driving that and that will continue to support the utilization as we go into the future.
Speaker Change: There's an aging population, there's high rates of disease prevalence and continue to see improvements in advanced diagnostics and our specialty testing areas, including things like companion diagnostics. So I think those market factors actually support a healthy utilization environment in <unk>.
Julia Wang: So I think those market factors actually support a healthy utilization environment. In addition to that, I believe that we will continue to kind of continue to get some market share. So not only do I think we'll grow with the market, I think we'll continue with the hospital business and the laboratory business that we're doing to find ways to grow a bit faster than the overall market. And the one comment I'd like to add is, to Adam's point, we do expect the strong utilization to continue into the second half of the year as part of our guide.
Speaker Change: Listen to that I believe that we will continue to.
Speaker Change: Continue to get some market share so not only do I think we will grow with the market I think we will continue with the hospital business in the laboratory business that we're doing to find ways to grow a bit faster than the overall market.
Speaker Change: And the one comment I'd like to add is to <unk> point we.
Speaker Change: Do you expect this fall <unk> line inflation took continuing into the second half of the year as part of our buy that's why when you look at the mid point of our EPS. We've raised the full year guide by 23 says, it's really driven by the continued strength and our utilization along with the other momentum.
Julia Wang: That's why, when you look at the midpoint of our EPS, we raised the full-year guide by $0.23. It's really driven by the continued strength in the utilization, along with other momentum. And when you look at the $0.23 bid and raise, actually about one-third is driven by operational strength, with the other balance coming from FX durability.
Speaker Change: And when you look at the 23 feet and we.
Speaker Change: It's actually about one third is driven by operational strength with the other that is coming from FX the liability.
Speaker Change: Yeah.
Erin Wright: Okay, great. Thank you so much. Thank you.
Speaker Change: Okay, great. Thank you so much.
Speaker Change: Thank you.
Speaker Change: Okay.
Michael Ryskin: And our next question comes from Michael Ryskin of Bank of America. Your line is open. Morning, Michael. Great. Morning. Thanks for squeezing me in, guys. A couple of small questions tying up stuff you touched on earlier. I think in one of the very early comments, you provided some color on PAMA and how you see that playing out, you know, very What do you think the net impact of O&M would be on intent-oriented trading? Could you expand on that a little bit, whether it's the cost controls or the volume mix?
Speaker Change: And our next question comes from Michael Riskin of Bank of America. Your line is open good.
Speaker Change: Good morning, Michael.
Speaker Change: Good morning.
Speaker Change: Thanks for squeezing me in guys a couple of small questions tying up question touched on earlier.
Speaker Change: And one very early comments you provided some color on Panama and how you see that playing out very consistent with what you said in the past, but if you could just expand a little bit more likely that it feels like it's a little more likely like we're going to have to deal with this next year.
Speaker Change: Talking about some of those offsets via launch pad et cetera.
Speaker Change: Could you just sort of quantify that help us think through the timing of that when you implement those how those will be implemented.
Speaker Change: Sort of how that should play out in 2026.
Speaker Change: If this does come.
Speaker Change: Come back and take effect next year and sort of what the net impact would be and then the other question was going to be.
Speaker Change: Julien touched a couple of times on the strong margins in the quarter that really shone through.
Speaker Change: If you could expand on that just a little bit sort of whether it's the cost controls.
Speaker Change: Or the volume mix like how that contributed to the.
Speaker Change: 50 bps underlying accident.
Speaker Change: That'd be helpful. Thanks.
Adam Schechter: Yeah, so, Michael, first, let's start with PAMA. So, as I said before, we're going to do everything we can to work with ACLA to get the appropriate legislation through. We'll work with them if that doesn't occur to see if we can get another year of delay. And if that doesn't happen, we'll continue to work with them to see if there's a way to get the data more accurately presented or represented through getting more collection of data across the industry. All those three things would have an impact on what PAMA downside could be if it occurs next year.
Speaker Change: Yes, so Michael first I'll start with Panama, So yeah as I said before we're going to do everything we can work with <unk> to get the appropriate legislation through we'll work with them if that doesn't occur to see if we can get another year of delay and if that doesn't happen. We will continue to work with them to see if there's a way to get that data more accurately presented or represented.
Speaker Change: Get through getting more collection of data across the industry. All of those three things would have an impact on what Panama downside could be if that occurs next year. So it's hard to tell you in each of those scenarios what the impact would be what I would say is that if none of that works. The impact was a $100 million, we won't be able to offset that.
Julia Wang: So, it's hard to tell you in each of those scenarios what the impact would be. What I would say is that if none of that works, the impact is $100 million. We won't be able to offset the whole $100 million. We will work to do everything we can to offset as much of that as possible. The key is going to be we already have committed to $100 to $125 million in savings due to Launchpad, which we continue to commit to. This would be in addition to that. We have things that we're doing right now as we speak, putting in projects for artificial intelligence, looking at ways to drive revenue through a better customer experience, for ways to reduce costs through elimination of duplication and some other roles.
Speaker Change: $400 million.
Speaker Change: We will work to do everything we can to offset as much of that is possible. If he is going to be we already have committed to $100 million to $125 million in savings due to large pad, which we continue to commit to this would be in addition to that we have things that we're doing right now as we speak putting in projects for artificial intelligence looking at.
Speaker Change: At.
Speaker Change: Ways to drive revenue through a better customer experience for ways to reduce cost through elimination of duplication and some other roles. So we're working on a lot of things to offset Panama impairment does not a car, it's just going to be more momentum for us, but if it does we will do whatever we can to offset as much as possible and we'll be transparent.
Julia Wang: So, we're working on a lot of things to offset PAMA. If PAMA does not occur, it's just going to be more momentum for us. But if it does, we'll do whatever we can to offset as much as possible. And we'll be transparent with what we do as we provide 2026 guidance. And from a margin perspective, I think the short answer to your question is the contributions are coming from all those sources, specific speaking, obviously, the revenue growth is absolutely helpful in addition to the ability to drive operating efficiency through cost management. But I also think that heading to the second half, in addition to all those strengths and contributions, the fact that we will be overlapping with NVT annualizing in Q3 will enable us to deliver a margin expansion at a level in the second half that, once again, will enable us to deliver a full-year margin expansion, and we are very much looking forward to that expectation.
Speaker Change: And with what we do as we provide 2026 guidance.
Speaker Change: And from a margin perspective.
Speaker Change: I think the short answer to your question.
Speaker Change: Contributions are coming from all of those sources specific staking all the way see the revenue growth is absolutely. Helpful addition to the ability to drive operating efficiency and cost management.
Speaker Change: I also think that.
Speaker Change: Heading into the second half in addition to all of those as Jonathan the contributions. The fact that we will be overlapping with <unk>.
Speaker Change: Annualizing Q3 will enable us to be named by a margin expansion at the level in the second half that's a whatsapp that will enable us to deliver full year margin expansion and we are very much looking forward to.
Speaker Change: That's the expectation.
Adam Schechter: Thank you.
Adam Schechter: This concludes our question and answer session. I'd like to turn it back to Adam Schechter at this time for closing remarks. Thank you, DeeDee, and thank you everybody for joining us today. Hopefully you see we have momentum, we continue to focus on our strategy, and that our strategy is working. We look forward to seeing you all soon and continuing our discussions with you. Have a great day.
Speaker Change: Thank you. This concludes our question and answer session I would like to turn it back to Adam Schechter at this time.
Adam Schechter: We're closing on thank you Vijay and thank you everybody for joining US today, hopefully you see we have momentum we continue to focus on our strategy and that our strategy is working we look forward to seeing you all soon and continuing our discussions with you have a great day.
Operator: This concludes today's conference call. Thank you for participating and you may now disconnect.
Adam Schechter: This concludes today's conference call. Thank you for participating and you may now disconnect.
Adam Schechter: Okay.
Adam Schechter: Okay.
Adam Schechter: [music].
Adam Schechter: Okay.
Adam Schechter: [music].
Adam Schechter: Yes.
Adam Schechter: Okay.
Adam Schechter: [music].
Adam Schechter: Yes.
Adam Schechter: [music].
Adam Schechter: Yes.